-
Cost-Effectiveness Analysis of Isavuconazole vs. Liposomal Amphotericin B for the Treatment of Invasive Mucormycosis in Morocco
Sep 9, 2025, 16:22 PM -
Budget Impact of the VELYS™ Robotic-Assisted Solution Compared to Manual Procedure in Patients Undergoing Primary Total Knee Arthroplasty in Spain
Sep 9, 2025, 16:22 PM -
Navigating Uncertainty and Pragmatic Acceptance: Canadian Patient and Public Perspectives on Radiopharmaceutical Therapy in the Context of Whole Health
Sep 9, 2025, 16:22 PM -
Integration of Germany’s AMNOG Framework With the Joint Clinical Assessment Process
Sep 9, 2025, 16:22 PM -
A Systematic Literature Review of Cost of Illness Studies on Atrial Fibrillation With Focus on the Methodologies Economic Burden and Factors Influencing the Cost of Atrial Fibrillation Among European and North American Countries
Sep 9, 2025, 16:22 PM -
Use of Multilevel Network Meta Regression (ML-NMR) Model in RET Mutation-Positive Medullary Thyroid Cancer (MTC)
Sep 9, 2025, 16:22 PM -
Competing Beyond the First Mover: How Late to Market Analogues Navigate Pricing and Access in Major Global Markets
Sep 9, 2025, 16:22 PM -
The Role of Regulatory Entities in Global Vaccine Availability
Sep 9, 2025, 16:22 PM -
Listening to the Voice of the Patient: Insights From a Survey on the Burden of Recurrent Respiratory Papillomatosis in the United States
Sep 9, 2025, 16:22 PM -
The Greek Drug Price Negotiation Committee and Its Contribution in Optimizing the Management of EOPYY's Pharmaceutical Budget
Sep 9, 2025, 16:22 PM -
Evaluation of Participation Data in the Context of Cancer Prevention
Sep 9, 2025, 16:22 PM -
Real-World Uptake of SGLT2i Usage in Patients With Chronic Kidney Disease or Heart Failure: A German Claims Data Analysis
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Follow-up Strategies for Localized or Locally Advanced Renal Cell Carcinoma From the UK NHS Perspective
Sep 9, 2025, 16:22 PM -
Challenges at the Interface Between EUHTA (JCA) and National HTA in Germany (AMNOG): Expected Limitations to Synergy Effects and Implications for AMNOG Dossier Preparation
Sep 9, 2025, 16:22 PM -
Randomized Controlled Trials (RCTs) Are the Gold Standard: Are They Always Used?
Sep 9, 2025, 16:22 PM -
Budgetary Impact of Generalized Pustular Psoriasis (GPP) in the Brazilian Private Healthcare System: A Real-World Data Analysis
Sep 9, 2025, 16:22 PM -
How Health Policy Influences HTA Outcomes: Comparative Insights From Ukraine, Moldova, and Bulgaria
Sep 9, 2025, 16:22 PM -
Economic Burden of Prostate Cancer Overall and by Stages Based on the French Real-World Nationwide Medico-Administrative Database (SNDS)
Sep 9, 2025, 16:22 PM -
The Impact of Inhaler Technique on the Health Outcomes and Cost Among Adults With Asthma and Chronic Obstructive Pulmonary Disease in Saudi Arabia
Sep 9, 2025, 16:22 PM -
Systematic Review of Real-World Data on the Effectiveness and Safety Profiles of First-Line Therapies in Chronic Lymphocytic Leukemia
Sep 9, 2025, 16:22 PM
